You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《大行报告》瑞银上调信达生物(01801.HK)目标价至132.9元 降诺诚健华(09969.HK)评级至「中性」
阿思达克 03-08 09:52
瑞银发表的研究报告指,内地领先的生物科技公司研发能力及资产均获国际企业认可,而这些企业亦开始进入大型国际品牌医药市场,认为百济神州(06160.HK)、信达生物(01801.HK)、君实生物(01877.HK)及诺诚健华(09969.HK)发展产品线进展均理想。

随着信达生物开展与礼来合作,百济神州及君实生物亦分别与Novartis及Coherus合作,合作总额分别达22亿美元及11亿美元。该行相信海外合作可为研发、注册及市场策略等带来支持,同时可助将本地PD-1产品带往海外市场。

瑞银指出该行所覆盖的公司产品线开发上进展均理想,相信监管层面将有更多正面消息及数据,予百济神州美股(BGNE.US)、信达生物及君实生物「买入」评级,但就将诺诚健华评级由「买入」降至「中性」,四家公司目标价全线上调(另见附表)。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account